A multicenter, randomized, placebo-controlled, double-blind, comparative study of dienogest at 1 mg/day in patients with primary and secondary dysmenorrhea

Condition tags

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

• Diagnosis and initial management of dysmenorrhea. via openalex
• Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex
• Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
• Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
• Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial via openalex
• Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial via openalex
• Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study via openalex
• Influence of Dienogest on Ovulation in Young Fertile Women via openalex
• Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial via openalex
• Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—A systematic enquiry and overview via openalex
• doi:10.3111/13696998.2013.830974 via openalex
• doi:10.1111/j.1447-0578.2007.00189.x via openalex
• doi:10.2147/ijwh.s70935 via openalex
• W2582648508 via openalex
• W6603047530 via openalex
• W6676680339 via openalex
• W7075729153 via openalex
• doi:10.1111/jog.13406 via openalex
• doi:10.1136/bmj.e4944 via openalex
• doi:10.1093/humupd/dmv039 via openalex
• doi:10.1016/j.thromres.2015.09.011 via openalex
• doi:10.1136/bmj.d6423 via openalex
• doi:10.1136/bmj.b2890 via openalex
• doi:10.1016/j.fertnstert.2011.02.045 via openalex
• doi:10.1111/j.1447-0756.2009.01076.x via openalex
• doi:10.1002/14651858.cd001751.pub3 via openalex
• doi:10.1136/bmj.332.7550.1134 via openalex
• doi:10.1016/j.contraception.2006.12.008 via openalex
• doi:10.1136/bmj.b2921 via openalex

Cited by (4)

• Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial (Preprint) 2024
• Effects of Dienogest on Breasts of Women of Reproductive Age: A Cohort Study 2022
• Efficacy of Low-Dose Estrogen–Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis 2022
• Long‐term use of dienogest for the treatment of primary and secondary dysmenorrhea 2020

Source provenance

openalex

last seen: 2026-05-14T06:27:26.827241+00:00